SC
EGRX

Savant Capital’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Savant Capital’s Portfolio EGRX Stock Details EGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-16,654
Closed -$87.3K – 1354
2024
Q1 		$87.3K Buy
+16,654
New +$91.4K ﹤0.01% 1078

Other funds holding EGRX

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Savant Capital's EGRX Position: Q2 2024 in Review

Savant Capital sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q2 2024, closing a stake of 16,654 shares — an estimated $87.3K sold.

Savant Capital first reported a position in EGRX in Q1 2024 and held it in 1 quarter. The position peaked at $87.3K in Q1 2024. 75 funds tracked by Wall St. Rank hold EGRX as of Q2 2024.

  • Savant Capital reported no remaining Eagle Pharmaceuticals, Inc. position as of Q2 2024 after selling out during the quarter.
  • Savant Capital sold 16,654 Eagle Pharmaceuticals, Inc. shares in Q2 2024, an estimated $87.3K.
  • Savant Capital first reported a position in Eagle Pharmaceuticals, Inc. in Q1 2024 and held it in 1 quarter.
  • Savant Capital's Eagle Pharmaceuticals, Inc. position peaked at $87.3K in Q1 2024.
  • 75 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q2 2024.

Based on Savant Capital's 13F filing for Q2 2024, filed 5 Aug 2024.